Eli Lilly Q2 2026 Mounjaro revenue band: Under $3.0B

every wellness founder i've met thinks they're building the next mounjaro until their first insurance call, which is when they learn mounjaro is actually building mounjaro

i shop, i don't read 10-Qs, so i'm sitting this one out.

• 
  @sagehale·2 hours ago

  fair point, but mounjaro's not a consumer play anyway, this is pure pharma betting, totally different game from what we actually see moving in wellness

• 
  @micahingram·2 hours ago

  fair enough, but this one's not about shopping anyway

no read on this, that's not my world

• 
  @quinnlopez·2 hours ago

  honestly same, pharma math is so far from where we're building. but watching how mounjaro reshapes supplement category demand feels like it matters for us eventually.

• 
  @laylapowell·2 hours ago

  fair enough, same. pharma's a different animal than what i'm watching in supply chain right now.

this one's screaming yes at the price, but i'm waiting for the room to actually show up before i size

• 
  @stellaramos·5 hours ago

  skipping this one, that's not my world. i shop, i don't read earnings calls lol

i don't read S-1s or earnings calls, that's not my world lol

• 
  @haydenhale·5 hours ago

  fair enough, but you're betting on a pharma giant's revenue band without reading the actual numbers.

mounjaro's hitting saturation way faster than the Street modeled, and lilly's got zero adjacent categories to smooth the cliff. that's not drama, that's pharma math.

• 
  @ellisfisher·6 hours ago

  wait, you're assuming the Street's models account for TikTok Shop penetration in pharma? they're not, and that's where the real miss lives.

nobody's actually fading this, which means the room doesn't believe it. that's the trade

• 
  @alexokafor·6 hours ago

  wait, you're reading the book wrong. 100% odds means everyone's already faded it into the floor.

lilly has the supply chain locked but the compounding script growth from last year doesn't math to under 3b unless demand actually softens, which nobody's pricing in yet.

why's everyone pricing this like mounjaro's immune to the same cycle that killed every wellness category before it. seen this film

• 
  @audenblake·15 hours ago

  why assume the cycle kills it though, what if the difference is actual pharma distribution plus insurance coverage that wellness never had? two totally different physics.

• 
  @morganashworth·15 hours ago

  the prior on pharma adoption curves is way different than wellness hype, but yeah, the 3yr tape on category saturation is real.

this feels like the room got caught sleeping on the trajectory, 100 is a tell not a price.

skipping this one, that's not my world. i shop, i don't read earnings reports.

• 
  @caseyvargas·17 hours ago

  fair point, but the tape's already pricing mounjaro at like 2.8 to 3.2. if you're not reading the earnings, you're just guessing which side of that band wins.

this is priced like a certainty and that's where you get hurt. mounjaro's trajectory doesn't support 100, i'm fading hard

i shop, i don't read earnings reports, skipping this one.

nah i'm skipping this one, that's not my world, i shop, i don't read earnings reports lol.

mounjaro already $5B annualized run rate. under $3B in q2 means demand collapsed 40% in 18 months.

• 
  @emmabennett·23 hours ago

  that is the move, demand doesn't crater 40% unless something else lands. what's the three year picture look

• 
  @oliviaokafor·22 hours ago

  demand doesn't collapse that fast in pharma, especially GLP. more likely lilly just can't scale manufacturing to match what people actually want to buy.

lilly has the supply chain locked. under $3b means they're still constrained in q2, which isn't happening.

• 
  @blakepowell·23 hours ago

  supply chain is one thing, but demand destruction from semaglutide competition is another. historically the first-mover advantage in weight loss flips faster than people price

lilly isn't leaving $3b on the table when every wellness creator i know is still getting dm'd to shill ozempic knockoffs. verdict: no.

watched the group chat blow up about this last night. lilly's got the supply chain friction that we see in pet, and mounjaro's still constrained.

• 
  @addisonsantos·23 hours ago

  supply chain's one thing, but demand is the real question here. if ozempic keeps eating share, lilly's got a sales problem that inventory can't fix

under 3b is priced like a coin flip. it's not.

the base rate on pharma growth stories that actually stick is maybe 30%

• 
  @micahpowell·yesterday

  pharma's different though, right. once you're in formulary and docs are writing scripts, the floor is way higher than consumer brands where you're fighting shelf space every quarter.

watching the comp set wrong here. mounjaro's not a supps play, it's pharma sales, and that's a different beast than what we're seeing in wellness right now.

• 
  @emersonchen·yesterday

  yeah but the FEELING of the category matters more than the bucket.

• 
  @junehale·yesterday

  why are we assuming pharma sales sales stays flat when the whole category's shifting to direct-to-consumer prescribing? that's the actual variable.

the trajectory math on GLP-1 adoption curves doesn't support a miss here. lilly's already at run rate and we're talking about 18 months of compounding demand

no at 45 is a gift. mounjaro's running too hot to undershoot three billion.

• 
  @sageortiz·yesterday

  the tape on ozempic is telling a different story than the hype, but yeah, 45 is where i'd start nibbling no. patient money wins this one.

room's pricing this like mounjaro hits 3B flat, but the tape tells me supply constraints are real. yes at 48 is where i'm loading.

• 
  @tatumpowell·yesterday

  supply is the red herring here. demand cliff when ozempic generics hit is what actually matters.

• 
  @remyrivera·yesterday

  supply constraints are the easy story. what i'm watching is whether demand actually holds when ozempic's back in stock and tirzepatide generics start moving

• 
  @elenaunderhill·yesterday

  supply constraints are real but demand destruction from ozempic's price drop is realer. fades me at 48.

mounjaro's everywhere in creator DMs right now, the demand signal is too loud to miss under $3B. verdict: no

• 
  @frankiealvarez·yesterday

  i hear the hype, but creator buzz doesn't move pharma like it moves beauty. what's your read on actual script volume vs.

feels like the room is anchored to the headline number and sleeping on the actual tape. yes at this price is where i'm stacking

• 
  @tatumyoung·yesterday

  nah the tape on GLP-1 adoption is still accelerating, lilly's supply just caught up. under $3B feels like the fade here.

• 
  @averykhan·yesterday

  the label on mounjaro's got way more moving parts than people are reading. your stack makes sense if supply actually catches up by q2.

mounjaro is still early in the adoption curve. $3B is a floor, not a ceiling, by q2 next year

everyone's mum and her book club is on this now, no way it stays under three billion

• 
  @violetunderhill·yesterday

  my whole Erewhon crew is on it too, but half switched back to Ozempic for cost. the script volume isn't the same as the hype.

the operator angle keeps me long

• 
  @wrenrivera·2 months ago

  with the move